Daily Clinical Updates from SABCS

		prIME Oncology invites you to view exciting news released from the San Antonio Breast Cancer Symposium.
		10 DECEMBER 2009
		This CME-certified expert interview with William J. Gradishar, MD, from the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and Stephen E. Jones, MD, from US Oncology in Dallas, Texas, discusses endocrine-responsive breast cancer focusing on the following data releases: Abstract #11: Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer Abstract #12: Disease Related Outcome with Long Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study (IES) Abstract #13: Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA.17 Trial Abstract #14: Treatment-Emergent Symptoms and the Risk of Breast Cancer—Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial Abstract #16: Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial View an Expert Interview and Opinion with William J. Gradishar, MD, and Stephen E. Jones, MD, and access the slides. Click here to complete the post-test online.
		11 DECEMBER 2009
		This CME-certified expert interview with Lee Lokey, MD, senior medical director at prIME Oncology in Atlanta, Georgia, and William J. Gradishar, MD, from the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, discusses the topic of advanced breast cancer focusing on the following data releases: Abstract #22: A Comparison of Denosumab Versus Zoledronic Acid on the Incidence of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases Abstract #23: First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole Versus Anastrozole at First Relapse in Hormone R Receptor Positive Breast Cancer Abstract #41: Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC) Abstract #42: RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer View an Expert Interview and Opinion with Lee Lokey, MD, and William J. Gradishar, MD, and access the slides Click here to complete the post-test online.
		12 DECEMBER 2009
		This CME-certified expert interview with Sunil Verma, MD, MSEd, FRCPC, from the University of Toronto in Toronto, Ontario, Canada, and Mark Pegram, MD, from the University of Miami Sylvester Comprehensive Cancer Center in Miami, Florida, discusses targeted therapy focusing on the following data releases: Abstract #44: A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer Abstract #45: SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC) Abstract #46: Phase III Randomized Trial of Sunitinib (SU) Vs. Capecitabine (C) in Patients (pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC) View an Expert Interview and Opinion with Sunil Verma, MD, MSEd, FRCPC, and Mark Pegram, MD, and access the slides. Click here to complete the post-test online.
		This CME-certified expert interview with Mohammed Jahanzeb, MD, FACP, from Aptium Oncology in Boca Raton, Florida, and Giuseppe Viale, MD, PhD, from the University of Milan School of Medicine in Milan, Italy, discusses the topic of prognostic and predictive tools focusing on the following data releases: Abstract #33: Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium Abstract #74: Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC Abstract #75: The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy Abstract #76: Central Review of ER, PgR and HER2 in BIG 1-98 Evaluating Letrozole vs. Letrozole Followed by Tamoxifen vs. Tamoxifen Followed by Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer Abstract #112: Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100) View an Expert Interview and Opinion with Mohammed Jahanzeb, MD, FACP, and Giuseppe Viale, MD, PhD, and access the slides Click here to complete the post-test online.
		This CME-certified expert interview with Mohammed Jahanzeb, MD, FACP, from Aptium Oncology in Boca Raton, Florida, and Harold J. Burstein, MD, PhD, from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the topic of HER2-positive breast cancer focusing on the following data releases: Abstract #61: Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy Abstract #5081: Safety and Efficacy of Neratinib (HKI-272) in Combination With Paclitaxel in ErbB2+ Metastatic Breast Cancer Abstract #5095: Safety and Efficacy of Neratinib (HKI-272) in Combination With Vinorelbine in ErbB2+ Metastatic Breast Cancer Abstract #5085: An Evaluation of the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2+ Metastatic Breast Cancer Abstract #710: A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody–Drug Conjugate, in Patients with HER2+ Metastatic Breast Cancer who Were Previously Treated with an Anthracycline, a Taxane, Capecitabine, Lapatinib, and Trastuzumab Abstract #80: Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial Abstract #62: Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study View an Expert Interview and Opinion with Mohammed Jahanzeb, MD, FACP, and Harold J. Burstein, MD, PhD, and access the slides. Click here to complete the post-test online.